Chapters

Transcript

Video

What is the important, clinical and regulatory distinction between bioequivalency and interchangeability as it relates to biosimilar drugs and their reference product?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Jonathan Kay, MD

Jonathan Kay, MD

Director of Clinical Research
Rheumatology Division
Professor of Medicine
University of Massachusetts Medical School
Worcester, MA